Method and composition for treating seizure disorders
A composition for treating seizure disorders such as epilepsy comprises (i) an anticonvulsant drug of the hydantoin family; (ii) phytocannabinoid cannabidiol (CBD); and (iii) a fat-soluble vitamin.
1. Composition for treating a seizure disorder of a patient in need of such treatment, comprising:
(i) an anticonvulsant drug of the hydantoin family in an amount of not greater than about 2 mg/kg of the patient's body weight, which is effective to reduce seizure intensity and/or frequency;
(ii) phytocannabinoid cannabidiol (CBD) in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight;
(iii) a water-soluble vitamin in an amount of about 0.5 to about 1.0 mg/kg of the patient's body weight; and
(iv) a fat-soluble vitamin.
2. Composition of claim 1 wherein the anticonvulsant drug is selected from the group consisting of ethotoin, fosphenytoin, mephenytoin and phenytoin.
3. Composition of claim 1 wherein CBD is extracted from Cannabis indica or Cannabis sativa or a hybrid of Cannabis indica and Cannabis sativa.
4. Composition of claim 1 wherein CBD is synthetic CBD.
5. Composition of claim 1 wherein the fat-soluble vitamin is selected from the group consisting of vitamins A, D, E and K.
6. Composition of claim 1 wherein the fat-soluble vitamin is vitamin A.
7. Composition of claim 1 wherein the fat-soluble vitamin is in an amount effective to inhibit degradation of the anticonvulsant drug.
8. Composition of claim 1 wherein the water-soluble vitamin is selected from the group consisting of folic acid, folate, vitamin B9 and vitamin B12.
9. Composition of claim 8 wherein the water-soluble vitamin is folic acid.
10. Composition of claim 1 wherein the fat-soluble vitamin is in an amount of about 100-2000 IU/kg of the patient's body weight.
11. Composition for treating a seizure disorder of a patient in need of such treatment, comprising:
(i) an anticonvulsant drug of the hydantoin family in an amount of not greater than about 7 mg/kg of the patient's body weight, which is effective to reduce seizure intensity and/or frequency;
(ii) phytocannabinoid cannabidiol (CBD) in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight;
(iii) a water-soluble vitamin in an amount of about 0.5 to about 1.0 mg/kg of the patient's body weight; and
(iv) a fat-soluble vitamin in an amount of about 100-2000 IU/kg of the patient's body weight.
12. Composition of claim 11 wherein the anticonvulsant drug is selected from the group consisting of ethotoin, fosphenytoin, mephenytoin and phenytoin.
13. Composition of claim 11 wherein CBD is extracted from Cannabis indica or Cannabis sativa or a hybrid of Cannabis indica and Cannabis sativa.
14. Composition of claim 11 wherein CBD is synthetic CBD.
15. Composition of claim 11 wherein the amount of CBD is sufficient to inhibit degradation of the anticonvulsant drug.
16. Composition of claim 11 wherein the fat-soluble vitamin is selected from the group consisting of vitamins A, D, E and K.
17. Composition of claim 11 wherein the fat-soluble vitamin is vitamin A.
18. Composition of claim 11 wherein the fat-soluble vitamin is in an amount effective to inhibit degradation of the anticonvulsant drug.
19. Composition of claim 11 wherein the water-soluble vitamin is selected from the group consisting of folic acid, folate, vitamin B9 and vitamin B12.
20. Composition of claim 19 wherein the water-soluble vitamin is folic acid.
21. Composition of claim 11 wherein the seizure disorder is epilepsy.
22. Composition of claim 1 wherein the seizure disorder is epilepsy.
23. Method for treating a patient having a seizure disorder, comprising administering the composition of claim 1 to the patient.
24. Method of claim 23 wherein the seizure disorder is epilepsy.
25. Method for treating a patient having a seizure disorder, comprising administering the composition of claim 11 to the patient.
26. Method of claim 25 wherein the seizure disorder is epilepsy.